SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThe Mission Group Regulatory News (TMG)

Share Price Information for The Mission Group (TMG)

Share Price is delayed by 15 minutes
Get Live Data
17.50    0.00 (0.00%)
Bid:
17.00
Ask:
18.00
Spread: 1.00 (5.882%)
Market Cap: £15.85m
TMG Live PriceLast checked at - London Stock Exchange

Intraday The Mission Group Share Chart

Form 8.3 - Mission Group PLC

21 May 2024 11:33

RNS Number : 3044P
DBAY Advisors Limited
21 May 2024
Β 

FORM 8.3

Β 

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

DBAY Advisors Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Pershing Nominees Ltd for Fixtaia Ltd and Logistics Development Group plc under the discretionary management of DBAY Advisors Limited.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Mission Group Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

20 May 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

Β 

Β 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Β 

1p Ordinary

Β 

Β 

Interests

Short positions

Β 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

8,994,359

9.75

Β 

Β 

(2) Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

Β 

TOTAL:

8,994,359

9.75

Β 

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b) Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchase/sale

Β 

Number of securities

Price per unit

10p Ordinary Shares

Sale

172,475

23.68p

Β 

(b) Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

Β 

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

(ii) Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β None

Β 

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

Β 

(c) Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Β 

Β 

Date of disclosure:

21 May 2024

Contact name:

Michael Haxby

Telephone number*:

01624 602132

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETBFLFLZELXBBL
Date   Source Headline
19th Sep 20137:00 amRNSInterim results for the six months to 30 June 2013
30th Aug 20137:00 amRNSNotice of Interim Results
19th Jul 20137:00 amRNSDirector Exercise of Options & EBT dealing
17th Jul 20137:00 amRNSDirector Dealing
16th Jul 20137:00 amRNSDirectors' Exercise of Options
12th Jul 20137:00 amRNSDirector/PDMR Shareholding
11th Jul 20134:11 pmRNSAnnual LTIP Awards and Vesting; EBT Share Dealings
11th Jul 20137:00 amRNSDirector/PDMR Shareholding
10th Jul 20137:00 amRNSTrading Update
17th Jun 201312:30 pmRNSResult of AGM
12th Apr 20134:45 pmRNSDirector/PDMR Shareholding
11th Apr 20134:55 pmRNSDirector Dealing
10th Apr 20137:00 amRNSDirector Shareholding
3rd Apr 20137:00 amRNSDirector/PDMR Shareholding
28th Mar 20137:02 amRNSDirectors' Dealing
27th Mar 20134:10 pmRNSRegistered Office & Availability of Annual Report
25th Mar 20137:00 amRNSFinal Results
22nd Mar 20138:36 amRNSReplacement Notice of Results
22nd Mar 20137:00 amRNSNotice of Results
6th Mar 20137:00 amRNSDirectorate Change
1st Mar 20137:00 amRNSDirectorate Change
28th Jan 20137:00 amRNSTrading Update
25th Jan 20137:00 amRNSNew Client win and further expansion
9th Nov 20127:00 amRNSDirector/PDMR Shareholding
5th Nov 20127:00 amRNSDirector/PDMR Shareholding
19th Oct 201211:44 amRNSHolding(s) in Company
16th Oct 20122:59 pmRNSHolding(s) in Company
12th Oct 20127:00 amRNSAcquisition, Placing and Board Appointment
24th Sep 20127:00 amRNSAcquisition of Addiction Worldwide
19th Sep 20128:19 amRNSHalf Yearly Report
14th Sep 20123:14 pmRNSNotice of Half Year Results
20th Jul 20127:00 amRNSIssue of LTIP Awards
18th Jul 20127:01 amRNSPre Close Trading Update
18th Jul 20127:00 amRNSChange of Adviser
18th Jun 20121:03 pmRNSResult of AGM
18th Jun 201212:00 pmRNSDirectorate Change
31st May 20121:30 pmRNSContract Award
14th May 20124:04 pmRNSDirector/PDMR Shareholding
8th May 20122:01 pmRNSDirector/PDMR Shareholding
4th May 20122:47 pmRNSDirector/PDMR Shareholding
1st May 20127:00 amRNSDirector/PDMR Shareholding
16th Apr 20123:34 pmRNSHolding(s) in Company
27th Mar 20127:00 amRNSFinal Results
22nd Mar 20127:00 amRNSNotice of Results
26th Jan 20127:00 amRNSTrading Statement
24th Jan 20127:00 amRNSDirector/PDMR Shareholding
6th Jan 20129:13 amRNSDirector/PDMR Shareholding
21st Nov 20114:17 pmRNSDirector/PDMR Shareholding
3rd Oct 20112:44 pmRNSDirector/PDMR Shareholding
30th Sep 20117:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.